



Welcome!

While we wait to start, please review ways to navigate this webinar.

If you move your **cursor** to the **bottom** of **your screen** you will see a **menu**.




This menu allows you to **control**:

- React (“**Raise Hand**” is under this option)
- Access to the **Chat** box


Camera options are not available for participants. Participants can be unmuted by raising their hand and being recognized by the presenter.



Housekeeping



This session is being recorded to **Tomorrow's Healthcare.**



If you used a forwarded link, we need your **email address.**



Pose questions in the chat to **all participants.**



Please complete the post-session **evaluation.**



Disclosures



No members of the planning committee, speakers, presenters, authors, content reviewers, and/or anyone else in a position to control the content of this education activity have relevant financial relationships with any entity producing, marketing, re-selling, or distributing health care goods or services, used on, or consumed by, patients to disclose.



University of
Pittsburgh®

School of Pharmacy
Implementation and Research
Center for Healthy Communities



Disclaimer

The information presented at this Center for Continuing Education in Health Sciences program represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by, the UPMC Center for Continuing Education in the Health Sciences, UPMC/University of Pittsburgh Medical Center or affiliates and University of Pittsburgh School of Medicine. Reasonable efforts have been taken intending for educational subject matter to be presented in a balanced, unbiased fashion and in compliance with regulatory requirements. However, each program attendee must always use their own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses, and any off-label uses.



University of
Pittsburgh

School of Pharmacy
Implementation and Research
Center for Healthy Communities



Mutual Agreement

- Everyone on every Learning Network webinar is **valued**. Everyone has an expectation of **mutual, positive regard** for everyone else that respects the **diversity** of everyone on the webinar.
- We operate from a **strength-based, empathetic, and supportive** framework – with the people we serve, and with each other on these webinars.
- We encourage the use of **affirming language** that is not discriminatory or stigmatizing.
- We treat others as **they would like to be treated** and, therefore, avoid argumentative, disruptive, and/or aggressive language.





Mutual Agreement (continued)

- We strive to **listen** to each person, avoid interrupting others, and seek to **understand** each other through the Learning Network as we work toward the highest quality services for Centers of Excellence (COE) clients.
- Information presented in Learning Network sessions has been vetted. We recognize that people have different opinions, and those **diverse perspectives** are welcomed and valued. Questions and comments should be framed as **constructive feedback**.
- The Learning Network format is **not conducive to debate**. If something happens that concerns you, **please send a chat during the session** to the panelists and we will attempt to make room to address it either during the session or by scheduling time outside of the session to process and understand it. **Alternatively, you can reach out offline to your University point of contact.**





Acknowledgements

- The COE project is a partnership of the University of Pittsburgh's Program Evaluation and Research Unit and the Pennsylvania Department of Human Services; and is funded by the Pennsylvania Department of Human Services, grant number 601747.
- COE vision: The Centers of Excellence will ensure care coordination, increase access to medication-assisted treatment and integrate physical and behavioral health for individuals with opioid use disorder.



Pennsylvania
Department of Human Services



University of
Pittsburgh®

School of Pharmacy
Implementation and Research
Center for Healthy Communities



Retention Strategies



Learning Objectives

By the end of this training, you will be able to do the following:

Identify the benefits of sustained client engagement in substance use treatment and the care manager's role in supporting it.

Examine individual, social, and systemic risk factors associated with treatment and care management disengagement.

Apply evidence-based care management strategies to prevent and respond to disengagement





Background



University of
Pittsburgh

School of Pharmacy
Implementation and Research
Center for Healthy Communities

Client Engagement

Engagement = active participation

Enrollment = entering treatment

Retention = sustained participation over time





Treatment Gap

- In 2022, an estimated **6.1 million people** in the United States had an opioid use disorder¹
- In 2019, approximately **87%** of people with OUD did not receive MOUD¹
- Completion rates for SUD treatment: **~65%** for residential programs; only **~48%** for outpatient programs²
- These gaps represent critical opportunities for care managers to intervene



The Role of a Care Manager in Engagement

- **Comprehensive needs and SDOH assessment**
- **Individualized care planning**
- **Proactive outreach and monitoring**
- **Linkage to community resources**
- **Supporting care transitions**
- **Facilitating communication across providers**



Benefits of Engagement



University of
Pittsburgh

School of Pharmacy
Implementation and Research
Center for Healthy Communities



Survival

- Retention in MOUD treatment is associated with substantial reductions in all-cause and overdose mortality¹
- Compared to those not receiving MOUD after a nonfatal overdose:
 - Opioid-related deaths decreased by 59% for those receiving methadone
 - Opioid-related deaths decreased by 38% for those receiving buprenorphine¹
 - The period immediately following MOUD discontinuation carries the highest overdose mortality risk²



University of
Pittsburgh®

School of Pharmacy
Implementation and Research
Center for Healthy Communities



Improved Life Outcomes

- **Increased abstinence rates**
- **Decreased overdose-related ED visits**
- **Decreased arrests**





Reduced System Costs

- Low engagement = Higher costs
- **Care coordination** reduces unnecessary acute care by **connecting clients to the right support at the right time²**
- Engagement is both a **clinical** and **financial imperative²**



University of
Pittsburgh.

School of Pharmacy
Implementation and Research
Center for Healthy Communities



Recovery Capital

- **COEs build recovery capital**
- **Outreach, peer support, and wraparound services keep clients connected**
- **Care coordination bridges clinical care and community-based support**



Discussion Question



Think of a COE client who stayed engaged in care. What role did you play in keeping them connected?





Recognizing the Risk of Disengagement



University of
Pittsburgh

School of Pharmacy
Implementation and Research
Center for Healthy Communities



Early Warning Signs

- **Missed or frequently rescheduled treatment appointments, particularly MOUD dosing visits¹**
- **Failure to respond to outreach calls, texts, or messages¹**
- **Changes in housing stability or loss of contact information²**
- **Increasing crisis calls, ED visits, or justice involvement³**
- **Client expressing hopelessness, ambivalence, or that treatment "isn't working"¹**
- **Loss of insurance coverage or lapses in prescription coverage¹**
- **Caregiver or family reporting concerns about the client²**



University of
Pittsburgh.

School of Pharmacy
Implementation and Research
Center for Healthy Communities



Individual-Level Factors

- **Younger age, low motivation, and limited insight into SUD/ODU**
- **Co-occurring mental health conditions (depression, PTSD, anxiety) significantly increase dropout**
- **Internalized stigma is a key barrier to engagement and retention**





Relational & Social Factors

- **Weak therapeutic relationship or perceived provider stigma¹**
- **Social isolation and lack of family support predict disengagement¹**
- **Self-stigma and community stigma are documented barriers to MOUD retention²**



University of
Pittsburgh®

School of Pharmacy
Implementation and Research
Center for Healthy Communities



Systemic & Structural Factors

- **Rigid attendance requirements, prior auth delays, and limited MOUD access**
- **Fragmented care and staff turnover increase dropout risk**
- **COEs can identify friction points and advocate on the client's behalf**



University of
Pittsburgh

School of Pharmacy
Implementation and Research
Center for Healthy Communities



Risk Factors

Missing BARC-10

Missing ASAM LOCA

Substance Use Severity

ASAM LOCA Score

Criminal Justice Involvement




Ambivalence

A client who resists or minimizes is not a lost cause – they are at a decision point. Whether they feel respected rather than managed is one of the most influential factors in whether resistance softens.



Visible Behaviors
(What COEs observe)



Hidden Drivers
(Underlying ambivalence)

Minimizing or denying use.

Deflecting with anger, humor, or
silence.
Attending only under
pressure.

Pessimism about treatment
outcomes.

Disappearing after crisis
stabilizes.

Mistrust of care team or
system.



How Ambivalence Presents



Minimizing or denying substance use severity (Doron et al., 2022)



Pessimism "This won't work" or "I've tried before" (Doron et al., 2022)



Deflecting with anger, humor, or silence (SAMHSA, 2019)



Attending only under pressure from legal, family, work mandates, etc. (Hachtel et al., 2019)



Disappearing after crisis stabilizes (Doron et al., 2022)



Mistrust of the care team or system (Ifeagwazi et al., 2021)





Coercion

Perceived coercion — not formal mandate — **drives poor outcomes**; even voluntary clients can feel coerced (Hachtel et al., 2019)

Mistrust is a major barrier for involuntary clients; prior negative system experiences predict hostile or withdrawn behavior (Ifeagwazi et al., 2021)

Coercive approaches **amplify stigma, lower self-esteem, and increase disengagement** (Luciano et al., 2023)

Coerced clients can stay as long and do as well as voluntary clients when the **relationship is respectful and autonomy-supportive** (NIDA)





- SDOH



University of
Pittsburgh

School of Pharmacy
Implementation and Research
Center for Healthy Communities



When Survival Competes with Care

- When survival competes with care, survival wins.
- These are measurable barriers, not excuses.





SDOH Drive Disengagement

Housing instability disrupts contact, medication storage, and care continuity and is linked to worse OUD severity and lower MOUD uptake¹

Transportation barriers are a direct dropout driver travel times over 60 minutes increase dropout risk by 59%²

Economic instability limits ability to prioritize treatment, medications, and follow-up³

Criminal justice involvement disrupts care continuity and reduces MOUD access among justice-referred clients⁴

Social isolation reduces engagement, follow-through, and accountability in care plans⁵

Food insecurity competes with care capacity and worsens mental health outcomes⁵

(¹McLaughlin et al., 2021; ²Harwerth et al., 2023; ³Stanojlović & Davidson, 2021; ⁴Donahoe & Saloner, 2024; ⁵Park & Berkowitz, 2024)






SDOH and Stigma

Clients facing SDOH challenges often also carry the weight of **multiple layers of stigma**

- **Structural stigma-** policies and systems that disadvantage people with OUD
- **Provider stigma-** feeling judged or dismissed by healthcare staff
- **Self-stigma-** shame that makes asking for help feel impossible

COE care managers sit at a unique intersection —they can **address both**



University of
Pittsburgh

School of Pharmacy
Implementation and Research
Center for Healthy Communities



Strategies to Prevent and Address Disengagement



University of
Pittsburgh

School of Pharmacy
Implementation and Research
Center for Healthy Communities



Addressing SDOH for Retention

- **Screen at every contact not just intake¹**
- **Document SDOH barriers in the care plan¹**
- **Connect to community resources- housing, food, transportation, legal aid²**
- **Advocate with the care team when SDOH drives missed appointments³**
- **Use flexible, low-barrier outreach when instability disrupts contact²**

SDOH-driven disengagement is not lack of motivation




University of
Pittsburgh

School of Pharmacy
Implementation and Research
Center for Healthy Communities



Ongoing Needs Assessments and Care Plans

 High-performing programs use **systematic assessment and individualized care plans**¹

 **Screen with validated SDOH tools at intake and regularly**²

 **Document in shared care plans**²

 **Plans should reflect goals, preferences, barriers, and strengths**³

 **Address both the SUD treatment pathway and the social needs that affect it**



Protective Factors



**Mental Health
Services**



**Housing
Services**



**Transportation
Services**



Food Services



**Offsite/Virtual
Services**





Proactive Outreach and Monitoring

- **Don't wait!** Proactive outreach is essential; **follow up on no-shows** within 24–48 hours
- **Check in regularly** (call/text/telehealth)
- **Use data/EHR flags** to identify disengagement risk early
- **Engage trusted supports** (family/peers)
- **Collect alternate contacts** (locator forms)



University of
Pittsburgh®

School of Pharmacy
Implementation and Research
Center for Healthy Communities



Reengagement

- **Act fast¹**
- **Use nonjudgmental, open-ended outreach²**
- **Reassess and update the care plan²**
- **Ensure naloxone and safety planning²**
- **Build trust²**



University of
Pittsburgh.

School of Pharmacy
Implementation and Research
Center for Healthy Communities



Latterman Family Health Center

Dr. Heather Mikes, DO



School of Pharmacy
Implementation and Research
Center for Healthy Communities



Philosophy

Everyone who comes to our clinic has made the important decision to work on their recovery.



University of
Pittsburgh

School of Pharmacy
Implementation and Research
Center for Healthy Communities



Signs of Disengagement

Decreased
communication

Inconsistent
attendance

Transportation
barriers

Concerning Bio
Feedback


Circumstantial
or MH crises

Partner return
to use



Four Key Areas to Retention

- When we think about how to support retention, we look at four key areas that shape our approach.
 - Scheduling
 - Environment
 - Relationship
 - SDOH



University of
Pittsburgh®

School of Pharmacy
Implementation and Research
Center for Healthy Communities



Scheduling



Missed visits are met with understanding, not shame.



Outreach is flexible, non-judgmental, and tailored to individual needs.



All forms of engagement and progress are celebrated.





Environment

- Recovery is unique to each person
- Squirrel Hill has adapted to each person to ensure that journey is supported



University of
Pittsburgh

School of Pharmacy
Implementation and Research
Center for Healthy Communities



Relationship



Meeting people where they are at



Staying flexible



Trust is earned, not owed





SDOH

- Adapt to individual needs and goals from the start
- Transportation is provided if needed
- Using community partnerships



University of
Pittsburgh

School of Pharmacy
Implementation and Research
Center for Healthy Communities



Addressing Ambivalence




**MEET STAGE
OF CHANGE**



**REDUCE
PRESSURE**



**FOCUS ON
RELATIONSHIP**



**BE A SAFE
SPACE**






Re-Engagement



3 outreach attempts



Multiple methods



Normalize disengagement




Celebrate return





Client Example

- Jane has been struggling with making it to her appointments recently...





Key Takeaways



University of
Pittsburgh

School of Pharmacy
Implementation and Research
Center for Healthy Communities



Key Takeaways



Disengagement is a clinical problem driven by distress, stigma, and social barriers, not lack of motivation.



The relationship determines the outcome. Respect and autonomy support matter more than how a client arrived.



Survival needs compete with care and survival wins; address SDOH, not just diagnosis.



SDOH and stigma compound each other and COEs sit at exactly that intersection.





Key Takeaways



The first 30 days are the highest-risk window; **proactive outreach is the strategy, not the backup plan.**



Screen continuously, not just at intake; SDOH circumstances change; care plans must keep up.



Resistance is ambivalence, not refusal. Respond with curiosity, not confrontation.



COEs are uniquely positioned to address what no other role in the system can.





Group Discussion

What is one area discussed today that you feel your COE could work to improve? How?





Questions





Wrap up and Next Session

- Please complete the **session evaluation**
- Slides and recording available on Tomorrow's Healthcare
- **Next Session:**





References

Agency for Healthcare Research and Quality. (2023). *Care coordination*. U.S. Department of Health and Human Services. <https://www.ahrq.gov/ncepcr/care/coordination.html>

Andersson, H. W., Wenaas, M., & Nordfjaern, T. (2018). Relapse after inpatient substance use treatment: A prospective cohort study among users of illicit substances. *Addictive Behaviors, 90*, 136–142. <https://doi.org/10.1016/j.addbeh.2018.10.032>

Brorson, H. H., Ajo Arnevik, E., Rand-Hendriksen, K., & Duckert, F. (2013). Drop-out from addiction treatment: A systematic review of risk factors. *Clinical Psychology Review, 33*(8), 1010–1024. <https://doi.org/10.1016/j.cpr.2013.07.007>





References

Centers for Medicare & Medicaid Services. (2023). *Health-related social needs screening tool*. U.S. Department of Health and Human Services. <https://www.cms.gov/priorities/innovation/data-and-reports/2023/ah-hrsn-screening-tool>

Davis, C. S., Carr, D., & Samuels, E. (2023). Opioid use disorder stigma reduction and treatment access: A policy and advocacy agenda. *Journal of Substance Abuse Treatment*, 147, Article 108737. <https://doi.org/10.1016/j.jsat.2022.108737>

Donahoe, R., & Saloner, B. (2024). Justice-involved populations and access to medications for opioid use disorder. *Health Affairs*, 43(2), 210–218. <https://doi.org/10.1377/hlthaff.2023.01051>





References

Doron, A., Afek, A., & Strous, R. D. (2022). Predictors of treatment dropout in a substance use disorder population: A systematic review. *Substance Abuse Treatment, Prevention, and Policy*, 17(1), Article 38. <https://doi.org/10.1186/s13011-022-00466-y>

Gottlieb, L. M., Wing, H., & Adler, N. E. (2020). A systematic review of interventions on patients' social and economic needs. *American Journal of Preventive Medicine*, 53(5), 719–729. <https://doi.org/10.1016/j.amepre.2017.05.011>

Hachtel, H., Harries, C., & Bhugra, D. (2019). Compulsory admissions and treatment in psychiatry and their impact on outcomes. *International Review of Psychiatry*, 31(5–6), 371–379. <https://doi.org/10.1080/09540261.2019.1654722>





References

Holdsworth, E., Bowen, E., Brown, S., & Howat, D. (2014). Client engagement in psychotherapeutic treatment and associations with client characteristics, therapist characteristics, and treatment factors. *Clinical Psychology Review, 34*(5), 428–450. <https://doi.org/10.1016/j.cpr.2014.06.004>

Ifeagwazi, C. M., Chukwuorji, J. C., & Zacchaeus, E. A. (2021). Mistrust and treatment engagement: Barriers among involuntary clients in substance use treatment. *Journal of Substance Use, 26*(4), 359–365. <https://doi.org/10.1080/14659891.2020.1832895>

Kindred Healthcare. (2021). *The relationship between patient engagement and total cost of care*. Kindred at Home.





References

Kreyenbuhl, J., Nossel, I. R., & Dixon, L. B. (2009). Disengagement from mental health treatment among individuals with schizophrenia and strategies for facilitating connections to care. *Schizophrenia Bulletin*, 35(4), 696–703. <https://doi.org/10.1093/schbul/sbp046>

Langabeer, J. R., Chambers, K. A., Cardenas-Turanzas, M., & Yatsco, A. (2025). Community health worker interventions for opioid use disorder: A systematic review. *Journal of Substance Abuse Treatment*, 160, Article 109370. <https://doi.org/10.1016/j.jsat.2024.109370>

Luciano, A., Nicholson, J., & Meara, E. (2023). Coercive practices in addiction treatment and their effects on stigma and self-esteem. *Psychiatric Services*, 74(3), 244–251. <https://doi.org/10.1176/appi.ps.202100657>





References

National Institute on Drug Abuse. (n.d.). *Principles of drug addiction treatment: A research-based guide* (3rd ed.). National Institutes of Health. <https://nida.nih.gov/publications/principles-drug-addiction-treatment-research-based-guide-third-edition>

Park, S., & Berkowitz, S. A. (2024). Social determinants of health and substance use disorder treatment outcomes: A systematic review. *Substance Abuse*, 45(1), 1–14. <https://doi.org/10.1080/08897077.2024.2301234>

Pew Charitable Trusts. (2020). *Medication-assisted treatment improves outcomes for patients with opioid use disorder*. <https://www.pewtrusts.org/en/research-and-analysis/issue-briefs/2020/11/medication-assisted-treatment-improves-outcomes-for-patients-with-opioid-use-disorder>





References

Rattray, N. A., Damush, T. M., Miech, E. J., Homoya, B., Meeker, J., & Myers, L. J. (2022). Beyond the blueprint: Mechanisms for spreading and sustaining care coordination innovations. *Journal of General Internal Medicine*, 37(Suppl 1), 147–155. <https://doi.org/10.1007/s11606-021-07230-7>

Sheridan, S. L., Harris, R. P., & Woolf, S. H. (2020). Shared decision making about screening and chemoprevention: A suggested approach from the U.S. Preventive Services Task Force. *American Journal of Preventive Medicine*, 26(1), 56–66. [https://doi.org/10.1016/s0749-3797\(03\)00250-0](https://doi.org/10.1016/s0749-3797(03)00250-0)

Stanojlović, M., & Davidson, L. (2021). Targeting the barriers in the substance use disorder continuum of care with peer recovery support. *SAGE Open Medicine*, 9, 1–18. <https://doi.org/10.1177/1178221820976988>





References

Substance Abuse and Mental Health Services Administration. (2019). *Enhancing motivation for change in substance use disorder treatment* (Treatment Improvement Protocol Series 35). U.S. Department of Health and Human Services. <https://store.samhsa.gov/product/tip-35-enhancing-motivation-change-substance-use-disorder-treatment/PEP19-02-01-003>

Substance Abuse and Mental Health Services Administration. (n.d.). *Recovery and recovery support*. U.S. Department of Health and Human Services. <https://www.samhsa.gov/find-help/recovery>

Tsai, A. C., Kiang, M. V., Barnett, M. L., Beletsky, L., Keyes, K. M., McGinty, E. E., Smith, L. R., Strathdee, S. A., Wakeman, S. E., & Venkataramani, A. S. (2019). Stigma as a fundamental hindrance to the United States opioid overdose crisis response. *PLoS Medicine*, 16(11), Article e1002969. <https://doi.org/10.1371/journal.pmed.1002969>





References

Vipond, R., Bhatt, M., Amlung, M., & MacKillop, J. (2023). Co-occurring mental health disorders and substance use disorder treatment dropout: A systematic review and meta-analysis. *Drug and Alcohol Dependence*, 243, Article 109740. <https://doi.org/10.1016/j.drugalcdep.2022.109740>

Wakeman, S. E., Larochele, M. R., Ameli, O., Chaisson, C. E., McPheeters, J. T., Crown, W. H., Azocar, F., & Sanghavi, D. M. (2020). Comparative effectiveness of different treatment pathways for opioid use disorder. *JAMA Network Open*, 3(2), Article e1920622. <https://doi.org/10.1001/jamanetworkopen.2019.20622>

